Skip to main content

Main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers

Secondary navigation

  • Value added services
  • CSR
  • About us

SearchSearch results for: “”

870 results

Stibbe advises KLM and Martinair

Representing KLM and its subsidiary Martinair in antitrust damage litigation in what is alleged to be Europe's largest ever cartel damage claim.

Stibbe advises AkzoNobel

Stibbe advises AkzoNobel in two applications for annulment brought by AkzoNobel in relation to the European Commission's decision in the heat stabilisers cartel.

Stibbe advises A-Lanes A15 Mobility

Stibbe advises A-Lanes A15 Mobility (Strabag, Strukton, Ballast Nedam) with regard to various discussions with Directorate-General for Public Works and Water Management (Rijkswaterstaat, RWS) in connection with the DBFM project A15 Maasvlakte-Vaanplein.

Stibbe advises on the IPO of ABN AMRO

Stibbe advises ABN AMRO, Deutsche Bank and Morgan Stanley (as joint global coordinators) and the other underwriters on the IPO of ABN AMRO.

Stibbe advises Hearthside Group Holdings in acquisition of VSI

Stibbe advises Hearthside Group Holdings LLC in the acquisition of VSI (B.V. Vurense Snack Industrie) from NPM Capital. Besides the majority stake of NPM Capital Hearthside also acquired the remaining shares.

Stibbe advises Egeria

Stibbe represents CEO of Royal Brinkers group of companies

Stibbe represented the director and sole shareholder of the Royal Brinkers group of companies in a insolvency litigation matter. In 2010, the majority of entities within the Royal Brinkers group went bankrupt as a result of changed market conditions.

Stibbe represents North Sea Port Netherlands

Stibbe represented North Sea Port Netherlands N.V in Supreme Court proceedings against Glencore AG concerning a right of pledge.

Stibbe represents Mylan

On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition

Stibbe advises Tribune Media Company

Advising Tribune Media Company and its subsidiary Gracenote, the world’s leading provider of entertainment data, on its acquisition of Infostrada Sports.

Stibbe advises FOD Economie

Representing the Belgian Ministry of Economy in a high-profile lawsuit against SABAM (the Belgian Society of Authors, Composers and Publishers) before the Brussels courts concerning the private collecting society’s compliance with the Belgian Copyright Ac

Stibbe advises companies with regard to investigations of the Social Affairs and Employment (SAE) Inspectorate

Providing legal assistance to several companies with regard to investigations of the Social Affairs and Employment Inspectorate (SAE, in Dutch: Inspectie Sociale Zaken en Werkgelegenheid) and imposed fines under the Foreign Nationals (Employment) Act. 

Stibbe advises Vodafone

Stibbe advises Vodafone Netherlands with the filing of a lawsuit with the Court of Rotterdam against the ACM in respect of its approval of KPN’s takeover of FTTH operator Reggefiber.

Stibbe advises Akzo Nobel

Stibbe advised Akzo Nobel in an action before the General Court to prevent the European Commission from publishing information originating from leniency documents.

Stibbe advises Ballast Nedam and Royal BAM

Succesfully defended Ballast Nedam and Royal BAM in legal proceedings against the Province of Groningen regarding the "Blauwe Stad" (Blue City).

Stibbe advises Credit Suisse

Stibbe advised Credit Suisse on the imposement of a fine by the European Commission for participating in a cartel involving interest rate products denominated in Swiss francs.

Stibbe advises Plantum

Stibbe advises Plantum (in its capacity as the Dutch association for the plant reproduction material sector) on the establishment of an International Licensing Platform (ILP)

Stibbe advises Mylan

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

Pagination

  • Previous page
  • Page 43
  • Current page 44
  • Page 45
  • Page 46
  • Next page
Reset filters
Date
Content type
  • Article (506)
  • Event (18)
  • Inside Stibbe (27)
  • Interview (1)
  • Matter (201)
  • Podcast (6)
  • People (111)
Expertise
  • (-) EU and Competition Law (488)
  • (-) Litigation and Arbitration (421)
  • Audit Firms and Accountancy (76)
  • Banking and Finance (422)
  • Capital Markets (243)
  • Compliance, Sanctions and Risk (161)
  • Corporate and M&A (857)
  • Corporate Investigations (31)
  • Criminal Law and Enforcement (141)
  • Digital Economy (106)
  • Employment, Benefits and Pensions (408)
  • Energy, Industry and Climate (308)
  • Environment and Planning (867)
  • ESG & Sustainability (289)
  • Financial Regulation (167)
  • Healthcare and Life Sciences (85)
  • Infrastructure and Mobility (193)
  • Insurance (36)
  • Intellectual Property (117)
  • Investment Funds (136)
  • Privacy and Data Protection (202)
  • Private Equity (196)
  • Procurement Law (122)
  • Public Law (1162)
  • Real Estate (465)
  • Restructuring and Insolvency (115)
  • Sports (25)
  • Stibbe StartsUP (29)
  • Tax (440)
  • Technology, Media and Telecommunications (327)
  • Unfair Competition and Consumer Protection (186)
Jurisdiction
  • BE Law (116)
  • EU Law (317)
  • LU Law (16)
  • NL Law (562)
Language
  • Dutch (119)
  • English (744)
  • French (7)

Footer main navigation

  • Expertise
  • Publications & Insights
  • People
  • Careers
© 2025 Stibbe

Footer navigation

  • Contact
  • Disclaimer
  • General Conditions
  • Register of legal practice areas
  • Privacy and Cookie Policy
  • Cookies Settings
  • Important Information